-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 25, 2021, TechnoMicrobiology announced that its self-developed "recombinant anti-tetanus toxin natural and fully human monoclonal antibody TNM002 injection" clinical trial application (IND) was officially obtained by the National Medical Products Administration ( NMPA) approval, this is the third country approved clinical trial of the drug after the approval of Australia and the United States.
Tetanus (Tetanus) is a specific infection in which Clostridium tetani invades the human body through skin or mucosal wounds, grows and reproduces in an oxygen-deficient environment, and produces Tetanus Toxin (TT), which causes muscle spasm.
According to incomplete statistics, only two regions in China and Southeast Asia use nearly 100 million "human-breaking" and "horse-breaking" units each year, and the market space is huge.
TNM002 is a recombinant anti-tetanus toxin natural human monoclonal antibody drug developed by Technolab using the HitmAb® technology platform.
As a natural fully human antibody, TNM002 can minimize the immunogenicity of antibody drugs and ensure the safety of the drug; as a genetically recombinant drug, TNM002 can use mammalian cell culture for large-scale production of modern industrial standards, compared to The quality of immunoglobulin is more controllable and the production cost is lower.
